Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Curtis Kephart

Sports Medicine Delray Beach, FL Medical Doctor

NPI 1396907762 CMS profile 17667

13590 Jog Rd Ste 7, Delray Beach, FL 33446

Open in the dashboard

General payments

$98,116

650 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,434 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Curtis Kephart of Delray Beach, FL is reported in the CMS Open Payments database as having received $98,116 across 650 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,434 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,461 69
2024 General $13,892 86
2023 General $7,436 81
2022 General $10,720 68
2021 General $6,386 59
2020 General $5,343 79
2019 General $36,878 208

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Curtis Kephart
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Curtis Kephart were reported at $17,461. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Curtis Kephart Sports Medicine median Middle half National median
2019 $36,878 $1,176 $199–$4,249 $163
2020 $5,343 $708 $96–$2,890 $114
2021 $6,386 $1,213 $152–$3,994 $132
2022 $10,720 $1,230 $159–$3,998 $149
2023 $7,436 $584 $146–$2,836 $160
2024 $13,892 $628 $163–$3,168 $164
2025 $17,461 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $41,869 204 payments
  2. Signature Orthopaedics USA Corp $9,600 1 payment
  3. Citieffe, Inc. $9,450 4 payments
  4. Arthrex, Inc. $7,122 19 payments
  5. Stryker Corporation $5,922 85 payments
  6. Royal Biologics $3,571 8 payments
  7. Southern Edge Orthopaedics, Inc. $2,529 4 payments
  8. Zimmer Biomet Holdings, Inc. $2,518 36 payments
  9. Patterson Companies, Inc. $2,500 3 payments
  10. Exactech, Inc. $1,727 8 payments
  11. Other $11,307 278 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $29,731 574 payments
  2. Consulting Fee $25,873 10 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,283 13 payments
  4. Travel and Lodging $11,401 47 payments
  5. Education $5,828 6 payments
Products named General payments · program years 2019–2025
  1. Navio Surgical System $20,069 53 payments
  2. Journey II BCS $16,579 17 payments
  3. Journey II XR $14,123 18 payments
  4. EBA One $9,450 4 payments
  5. Journey Uni $7,418 4 payments
  6. REAL INTELLIGENCE $6,047 59 payments
  7. VISIONAIRE Cutting Guides $5,025 4 payments
  8. VISIONAIRE Digital Templating $5,025 4 payments
  9. JOURNEY II $4,802 20 payments
  10. LEGION Revision $3,995 19 payments
  11. Other $47,380 578 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,176

Median for Orthopedic Surgery: 203

Drug cost

$7,196

Median for Orthopedic Surgery: $1,433

Branded share of claims

4.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 103 $1,825
Diclofenac Sodium Generic 178 $1,501
Meloxicam Generic 344 $876
Methylprednisolone Generic 111 $632
Gabapentin Generic 60 $590
Naproxen Generic 71 $439
Tizanidine Hcl Generic 92 $392
Ibuprofen Generic 45 $371
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 34 $251
Cyclobenzaprine Hcl Generic 35 $92

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$520,474

Of which drugs: $57,474

Medicare patients

767

Average age 78

Services billed

18,826

450 women, 317 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 40%
Chronic kidney disease 33%
Depression 32%
Diabetes 31%
Osteoporosis 25%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 100 9,781 $55,231
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 234 406 $2,244

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APONVIE
  • Heron Therapeutics, Inc. $61
$61 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $20
$20 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

650 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record